UNC Gillings School of Global Public Health: Paxlovid and Molnupiravir Substantially Reduced Hospitalization and Death From Omicron Variants
September 22, 2023
September 22, 2023
CHAPEL HILL, North Carolina, Sept. 22 (TNSres) -- The University of North Carolina's Gillings School of Global Public Health issued the following news:
New research conducted by the UNC Gillings School of Global Public Health and the Cleveland Clinic shows that ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir (Lagevrio) substantially reduced COVID-19 hospitalization and death among high-risk patients, even against the most recent Omicron subvariants BQ.1.1 and XBB.1.5 . . .
New research conducted by the UNC Gillings School of Global Public Health and the Cleveland Clinic shows that ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir (Lagevrio) substantially reduced COVID-19 hospitalization and death among high-risk patients, even against the most recent Omicron subvariants BQ.1.1 and XBB.1.5 . . .